Details of Disease

General Information of Disease (ID: DISMVL8O)

• Disease Name: Lymphoproliferative syndrome
• Synonyms: lymphoproliferative disorder; lymphoproliferative syndrome
• Definition: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).
• Disease Hierarchy:
  DISNGCMN: Inborn error of immunity
  DISMVL8O: Lymphoproliferative syndrome
• Disease Identifiers:
  MONDO ID: MONDO_0016537
  MESH ID: D008232
  UMLS CUI: C0024314
  MedGen ID: 6162
  HPO ID: HP:0005523
  Orphanet ID: 238510
  SNOMED CT ID: 277466009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bortezomib	DMNO38U	Approved	Small molecular drug	[1]
Rituximab	DM1YVZT	Approved	Antibody	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 34 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MS4A1	TTUE541	Limited	Biomarker	[3]
SPN	TTOZAX0	Limited	Biomarker	[4]
CBL	TT7QT13	moderate	Genetic Variation	[5]
CD200	TT0BE68	moderate	Biomarker	[6]
CXCL13	TT0NIZ1	moderate	Biomarker	[7]
EBP	TT4VQZX	moderate	Biomarker	[8]
FCER2	TTCH6MU	moderate	Altered Expression	[9]
SATB1	TTLFRIC	moderate	Altered Expression	[10]
TCL1A	TTUKRDV	moderate	Biomarker	[11]
XIAP	TTK3WBU	moderate	Altered Expression	[12]
ADA	TTLP57V	Strong	Biomarker	[13]
ADK	TTL732K	Strong	Biomarker	[14]
ALK	TTPMQSO	Strong	Biomarker	[15]
CASP8	TT6SZNG	Strong	Altered Expression	[16]
CBLB	TTHRAIJ	Strong	Genetic Variation	[17]
CD22	TTM6QSK	Strong	Biomarker	[18]
CD5	TTEGYK1	Strong	Altered Expression	[19]
CD52	TTQT5S9	Strong	Biomarker	[20]
CNTN2	TT2Z1WB	Strong	Altered Expression	[21]
FBXO11	TT6G10V	Strong	Altered Expression	[22]
FGR	TTPOGS1	Strong	Altered Expression	[23]
IL17A	TTG0MT6	Strong	Biomarker	[24]
ITK	TT3C80U	Strong	Genetic Variation	[25]
KIR2DL1	TT4UXPE	Strong	Altered Expression	[26]
KIR2DL2	TTU0P73	Strong	Altered Expression	[26]
KIR2DL3	TTEX3SI	Strong	Altered Expression	[26]
KIR2DS2	TTV3CFI	Strong	Altered Expression	[26]
LMO2	TTFX379	Strong	Genetic Variation	[27]
MLYCD	TT9Z4YD	Strong	Biomarker	[28]
PDCD1LG2	TTW14O3	Strong	Biomarker	[29]
PRAME	TTPH7T0	Strong	Biomarker	[30]
SERPING1	TTVQ6R9	Strong	Biomarker	[31]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[32]
ZAP70	TTUMHT8	Strong	Genetic Variation	[33]

This Disease Is Related to 3 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC27A5	DT0TQS3	Limited	Biomarker	[34]
ABCD1	DTKM9DZ	Strong	Biomarker	[35]
SLC35B2	DT81RKJ	Strong	Biomarker	[36]

This Disease Is Related to 49 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSBG1	OTM040MW	Limited	Biomarker	[37]
CCR10	OT7ZWSSD	Limited	Biomarker	[38]
IRF4	OT1DHQ1P	Limited	Biomarker	[39]
KNTC1	OTI2OOFN	Limited	Biomarker	[40]
KRT20	OT4RB40L	Limited	Biomarker	[3]
PARP9	OT7K4494	Limited	Biomarker	[34]
PDLIM7	OTAZVODU	Limited	Biomarker	[41]
PWWP3A	OTXQVL4U	Limited	Biomarker	[42]
RAPH1	OTMQXW7S	Limited	Biomarker	[37]
CD81	OTQFXNAZ	moderate	Biomarker	[43]
IBTK	OTB2GM4G	moderate	Biomarker	[44]
KLRB1	OTQ2959Y	moderate	Altered Expression	[45]
LAT	OTZC1XZ1	moderate	Biomarker	[46]
MTX1	OTLSDNZO	moderate	Biomarker	[47]
STIM1	OT8CLQ1W	moderate	Biomarker	[48]
TCL1B	OT4CSO39	moderate	Biomarker	[11]
ASAH2	OT47TIF3	Strong	Biomarker	[49]
BATF	OT9VSD2D	Strong	Biomarker	[50]
BCL3	OT1M5B95	Strong	Genetic Variation	[51]
CARD11	OTRCTLYC	Strong	Biomarker	[52]
CBFA2T2	OTNOIB23	Strong	Biomarker	[53]
CD5L	OTPY4WQR	Strong	Biomarker	[54]
CD84	OTAY5B0F	Strong	Genetic Variation	[55]
CHRDL1	OTGMWVVA	Strong	Biomarker	[56]
CIZ1	OT3UKHPI	Strong	Biomarker	[57]
CLEC4D	OTT7X1UC	Strong	Altered Expression	[58]
COIL	OTP4I4DL	Strong	Biomarker	[59]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[60]
DLX2	OTKC2DQ0	Strong	Altered Expression	[61]
DUSP22	OTEZ3U85	Strong	Biomarker	[39]
FAAP24	OTW6CO2I	Strong	Genetic Variation	[62]
GZMH	OTG3259L	Strong	Genetic Variation	[63]
HBZ	OTMHGFSS	Strong	Biomarker	[64]
IKZF1	OTCW1FKL	Strong	Altered Expression	[65]
KIR2DS3	OT3PSLDL	Strong	Biomarker	[66]
KLHDC8B	OTKP6LCR	Strong	Biomarker	[56]
KLRD1	OTMYLOV4	Strong	Altered Expression	[26]
MCU	OTQZAYWQ	Strong	Biomarker	[67]
MOS	OTNMQPFJ	Strong	Genetic Variation	[68]
ORC4	OT3ACTST	Strong	Genetic Variation	[69]
PAX7	OTDMQRPO	Strong	Posttranslational Modification	[70]
POU2AF1	OTOO6WHL	Strong	Biomarker	[71]
PPP1R12C	OT9Q86JO	Strong	Biomarker	[53]
PPP1R13B	OTC88VQO	Strong	Biomarker	[53]
RASGRP1	OTX9WN2E	Strong	Genetic Variation	[72]
SH2D1A	OTLU49I5	Strong	Biomarker	[73]
SLAMF1	OTBTT3ZQ	Strong	Genetic Variation	[74]
STIM2	OTYNXAW0	Strong	Biomarker	[48]
TIA1	OTGPN3P8	Strong	Biomarker	[26]

References

• [1] Bortezomib FDA Label
• [2] Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
• [3] Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.Leuk Lymphoma. 2019 Mar;60(3):573-582. doi: 10.1080/10428194.2018.1498490. Epub 2019 Jan 22.
• [4] Refining the Limits of Borderline Lymphoproliferative Disorders.Cytometry B Clin Cytom. 2019 Sep;96(5):351-358. doi: 10.1002/cyto.b.21760. Epub 2018 Dec 28.
• [5] A Case of Uveitis in a Patient With Juvenile Myelomonocytic Leukemia Successfully Treated With Adalimumab.J Pediatr Hematol Oncol. 2020 Jul;42(5):e373-e376. doi: 10.1097/MPH.0000000000001448.
• [6] Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2020 Sep;98(5):441-448. doi: 10.1002/cyto.b.21849. Epub 2019 Nov 6.
• [7] CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond.Front Endocrinol (Lausanne). 2019 Jul 12;10:471. doi: 10.3389/fendo.2019.00471. eCollection 2019.
• [8] Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation.Immunobiology. 1997 Dec;198(1-3):144-56. doi: 10.1016/s0171-2985(97)80035-6.
• [9] Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.Leuk Lymphoma. 2005 Feb;46(2):157-65. doi: 10.1080/10428190400010742.
• [10] SATB1 Defines a Subtype of Cutaneous CD30(+) Lymphoproliferative Disorders Associated with a T-Helper 17CytokineProfile.J Invest Dermatol. 2018 Aug;138(8):1795-1804. doi: 10.1016/j.jid.2018.02.028. Epub 2018 Mar 3.
• [11] Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.Cancer Res. 2006 Jan 15;66(2):915-20. doi: 10.1158/0008-5472.CAN-05-3426.
• [12] AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.Mol Cancer Ther. 2010 Apr;9(4):920-8. doi: 10.1158/1535-7163.MCT-09-1071. Epub 2010 Mar 30.
• [13] A new mixed inhibitor of adenosine deaminase produced by endophytic Cochliobolus sp. from medicinal plant seeds.Folia Microbiol (Praha). 2020 Apr;65(2):293-302. doi: 10.1007/s12223-019-00723-1. Epub 2019 Jul 4.
• [14] Adenosine deaminase: functional implications and different classes of inhibitors.Med Res Rev. 2001 Mar;21(2):105-28. doi: 10.1002/1098-1128(200103)21:2<105::aid-med1002>3.0.co;2-u.
• [15] Endobronchial pseudocarcinomatous hyperplasia mimicking squamous cell carcinoma associated with primary pulmonary ALK-negative anaplastic large cell lymphoma.Histopathology. 2020 Apr;76(5):781-784. doi: 10.1111/his.14032. Epub 2020 Mar 10.
• [16] Impaired apoptosis of lymphocytes derived from patient with decreased expression of caspase-8 results in Alps-like phenotype.Int J Mol Med. 2004 Nov;14(5):937-42.
• [17] Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.Oncogene. 2002 Feb 21;21(9):1423-33. doi: 10.1038/sj.onc.1205202.
• [18] Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.
• [19] Polymorphism in the CD5 gene promoter in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.Am J Clin Pathol. 2005 May;123(5):646-50.
• [20] Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.Mult Scler Relat Disord. 2019 Sep;34:100-102. doi: 10.1016/j.msard.2019.06.022. Epub 2019 Jun 18.
• [21] HTLV Tax gene expression in patients with lymphoproliferative disorders.J Clin Pathol. 1996 Nov;49(11):938-41. doi: 10.1136/jcp.49.11.938.
• [22] FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease.Blood. 2016 Aug 4;128(5):660-6. doi: 10.1182/blood-2015-11-684357. Epub 2016 May 10.
• [23] The proto-oncogene c-fgr is expressed in normal mantle zone B lymphocytes and is developmentally regulated during myelomonocytic differentiation in vivo.Blood. 1995 Jan 15;85(2):472-9.
• [24] Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes. Toxicol Appl Pharmacol. 2012 Aug 1;262(3):217-22. doi: 10.1016/j.taap.2012.05.004. Epub 2012 May 19.
• [25] Inherited Interleukin 2-Inducible T-Cell (ITK) Kinase Deficiency in Siblings With Epidermodysplasia Verruciformis and Hodgkin Lymphoma.Clin Infect Dis. 2019 May 17;68(11):1938-1941. doi: 10.1093/cid/ciy942.
• [26] Chronic T-cell lymphoproliferative disease expressing natural killer cell receptors: clinicopathological and molecular features.Cancer Genet Cytogenet. 2001 Sep;129(2):168-72. doi: 10.1016/s0165-4608(01)00451-4.
• [27] Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.Leuk Res. 2005 Jan;29(1):89-97. doi: 10.1016/j.leukres.2004.05.013.
• [28] Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.Orphanet J Rare Dis. 2019 Jul 11;14(1):173. doi: 10.1186/s13023-019-1145-y.
• [29] Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.Leuk Lymphoma. 2019 Feb;60(2):376-384. doi: 10.1080/10428194.2018.1480767. Epub 2018 Jul 22.
• [30] PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.Leuk Res. 2006 Nov;30(11):1333-9. doi: 10.1016/j.leukres.2006.02.031. Epub 2006 Apr 18.
• [31] Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.Med Oncol. 2018 Aug 2;35(9):118. doi: 10.1007/s12032-018-1183-7.
• [32] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.Hum Pathol. 2005 Oct;36(10):1113-9. doi: 10.1016/j.humpath.2005.08.005.
• [33] Dysregulation of Epstein-Barr Virus Infection in Hypomorphic ZAP70 Mutation.J Infect Dis. 2018 Jul 24;218(5):825-834. doi: 10.1093/infdis/jiy231.
• [34] Detection of MALT1 gene rearrangements in BAL fluid cells for the diagnosis of pulmonary mucosa-associated lymphoid tissue lymphoma.Chest. 2012 Jan;141(1):176-182. doi: 10.1378/chest.11-0068. Epub 2011 Jul 14.
• [35] Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer.Blood. 2000 May 15;95(10):3176-82.
• [36] Chronic lymphocytic leukaemia.Crit Rev Oncol Hematol. 2016 Aug;104:169-82. doi: 10.1016/j.critrevonc.2016.06.003. Epub 2016 Jun 16.
• [37] Use of eltrombopag for patients 65years old or older with immune thrombocytopenia.Eur J Haematol. 2020 Mar;104(3):259-270. doi: 10.1111/ejh.13370. Epub 2020 Feb 3.
• [38] CCR10 is expressed in cutaneous T-cell lymphoma.Int J Cancer. 2005 Jul 1;115(4):641-7. doi: 10.1002/ijc.20922.
• [39] DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.BMJ Case Rep. 2019 Sep 30;12(9):e230641. doi: 10.1136/bcr-2019-230641.
• [40] Immunophenotypic profiles for distinguishing orbital mucosa-associated lymphoid tissue lymphoma from benign lymphoproliferative tumors.Jpn J Ophthalmol. 2017 Jul;61(4):354-360. doi: 10.1007/s10384-017-0513-1. Epub 2017 Apr 18.
• [41] Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.Proc Natl Acad Sci U S A. 2017 May 2;114(18):4751-4756. doi: 10.1073/pnas.1701836114. Epub 2017 Mar 28.
• [42] Lymph node-based disease and HHV-8/KSHV infection in HIV seronegative patients: report of three new cases of a heterogeneous group of diseases.Int J Hematol. 2011 Jun;93(6):795-801. doi: 10.1007/s12185-011-0849-0. Epub 2011 Apr 21.
• [43] CD81(+) Exosomes Play a Pivotal Role in the Establishment of Hepatitis C Persistent Infection and Contribute Toward the Progression of Hepatocellular Carcinoma.Viral Immunol. 2019 Dec;32(10):453-462. doi: 10.1089/vim.2019.0077. Epub 2019 Nov 22.
• [44] Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.Can J Cardiol. 2018 Mar;34(3):337-341. doi: 10.1016/j.cjca.2017.12.001. Epub 2017 Dec 7.
• [45] Aberrant expression of NK cell receptors in Epstein-Barr virus-positive gammadelta T-cell lymphoproliferative disorders.Hematology. 2010 Feb;15(1):43-7. doi: 10.1179/102453310X12583347009450.
• [46] miR-155 Controls Lymphoproliferation in LAT Mutant Mice by Restraining T-Cell Apoptosis via SHIP-1/mTOR and PAK1/FOXO3/BIM Pathways.PLoS One. 2015 Jun 29;10(6):e0131823. doi: 10.1371/journal.pone.0131823. eCollection 2015.
• [47] Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.Rheumatology (Oxford). 2017 Jun 1;56(6):940-946. doi: 10.1093/rheumatology/kex002.
• [48] Stromal Interaction Molecule Deficiency in T Cells Promotes Spontaneous Follicular Helper T Cell Development and Causes Type 2 Immune Disorders.J Immunol. 2019 May 1;202(9):2616-2627. doi: 10.4049/jimmunol.1700610. Epub 2019 Mar 25.
• [49] Heavy-chain diseases.Hematol Oncol Clin North Am. 1999 Dec;13(6):1281-94. doi: 10.1016/s0889-8588(05)70127-1.
• [50] Overexpression of Batf induces an apoptotic defect and an associated lymphoproliferative disorder in mice.Cell Death Dis. 2012 May 17;3(5):e310. doi: 10.1038/cddis.2012.49.
• [51] Preclinical validation of fluorescence in situ hybridization assays for clinical practice.Genet Med. 2006 Jan;8(1):16-23. doi: 10.1097/01.gim.0000195645.00446.61.
• [52] Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.J Allergy Clin Immunol. 2015 Nov;136(5):1139-49. doi: 10.1016/j.jaci.2015.06.031. Epub 2015 Aug 12.
• [53] Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).Leukemia. 2002 May;16(5):894-901. doi: 10.1038/sj.leu.2402484.
• [54] Anti-interleukin-10 antibodies in patients with chronic active Epstein-Barr virus infection.J Infect Dis. 1997 Dec;176(6):1454-61. doi: 10.1086/514141.
• [55] CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.Clin Immunol. 2019 Jul;204:43-49. doi: 10.1016/j.clim.2018.10.017. Epub 2018 Oct 26.
• [56] Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types.Cancer Sci. 2017 Jun;108(6):1271-1280. doi: 10.1111/cas.13249. Epub 2017 May 23.
• [57] The nuclear matrix protein CIZ1 facilitates localization of Xist RNA to the inactive X-chromosome territory.Genes Dev. 2017 May 1;31(9):876-888. doi: 10.1101/gad.295907.117. Epub 2017 May 25.
• [58] The expression of PRAME in chronic lymphoproliferative disorders.Leuk Res. 2003 May;27(5):393-6. doi: 10.1016/s0145-2126(02)00217-5.
• [59] The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.J Cutan Pathol. 1997 Nov;24(10):597-603. doi: 10.1111/j.1600-0560.1997.tb01090.x.
• [60] Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.J Virol. 2005 Nov;79(22):13993-4003. doi: 10.1128/JVI.79.22.13993-14003.2005.
• [61] TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation.PLoS Pathog. 2015 May 21;11(5):e1004890. doi: 10.1371/journal.ppat.1004890. eCollection 2015 May.
• [62] Fatal Lymphoproliferative Disease in Two Siblings Lacking Functional FAAP24.J Clin Immunol. 2016 Oct;36(7):684-92. doi: 10.1007/s10875-016-0317-y. Epub 2016 Jul 29.
• [63] Characterization of a novel, human cytotoxic lymphocyte-specific serine protease cDNA clone (CSP-C).Tissue Antigens. 1990 May;35(5):220-8. doi: 10.1111/j.1399-0039.1990.tb01787.x.
• [64] HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia.JCI Insight. 2019 Oct 3;4(19):e128713. doi: 10.1172/jci.insight.128713.
• [65] A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.PLoS One. 2013 Jul 9;8(7):e68080. doi: 10.1371/journal.pone.0068080. Print 2013.
• [66] Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.PLoS One. 2015 Feb 20;10(2):e0117420. doi: 10.1371/journal.pone.0117420. eCollection 2015.
• [67] EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.Am J Surg Pathol. 2014 Nov;38(11):1522-9. doi: 10.1097/PAS.0000000000000282.
• [68] Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.Eur Arch Otorhinolaryngol. 1991;248(5):279-85. doi: 10.1007/BF00176755.
• [69] Novel ORC4L gene mutation in B-cell lymphoproliferative disorders.Am J Med Sci. 2009 Dec;338(6):527-9. doi: 10.1097/MAJ.0b013e3181b7f17c.
• [70] Evidence that general genomic hypomethylation and focal hypermethylation are two independent molecular events of non-Hodgkin's lymphoma.Oncol Res. 2004;14(7-8):399-405. doi: 10.3727/0965040041292323.
• [71] Heterogeneity of breakpoints at the transcriptional co-activator gene, BOB-1, in lymphoproliferative disease.Leukemia. 1996 Sep;10(9):1492-6.
• [72] Novel Mutations in RASGRP1 are Associated with Immunodeficiency, Immune Dysregulation, and EBV-Induced Lymphoma.J Clin Immunol. 2018 Aug;38(6):699-710. doi: 10.1007/s10875-018-0533-8. Epub 2018 Jul 20.
• [73] Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency.J Clin Invest. 2009 Oct;119(10):2976-89. doi: 10.1172/JCI39518. Epub 2009 Sep 14.
• [74] Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.J Med Virol. 2003 May;70(1):131-6. doi: 10.1002/jmv.10373.